Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas D Ross

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Molecular Pharmacology|December 4, 2003
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevisTakeo Nakanishi, L Austin Doyle, Bret Hassel, et al.
British Journal of Haematology|November 4, 2004
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survivalAttaya Suvannasankha, Hans Minderman, Kieran L O'Loughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2005
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cellsYuexing Zhang, Xin-Wei Wang, Danijela Jelovac, et al.
Cancer Research|July 23, 2003
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transportZhe-Sheng Chen, Robert W Robey, Martin G Belinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemiasKen Shiozawa, Takeo Nakanishi, Ming Tan, et al.
Molecular Pharmacology|November 15, 2012
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cellsAlex Man Lai Wu, Pooja Dalvi, Xiaoli Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trialJudith E Karp, Douglas D Ross, Weidong Yang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 10, 2011
Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residentsDouglas D Ross, Deborah W Shpritz, Susan D Wolfsthal, et al.
The Journal of Biological Chemistry|December 7, 2007
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cellsYingqiu Xie, Kexin Xu, Douglas E Linn, et al.
Molecular Pharmacology|July 19, 2003
Molecular modes of action of artesunate in tumor cell linesThomas Efferth, Axel Sauerbrey, Armin Olbrich, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Molecular Pharmacology|December 4, 2003
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevisTakeo Nakanishi, L Austin Doyle, Bret Hassel, et al.
British Journal of Haematology|November 4, 2004
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survivalAttaya Suvannasankha, Hans Minderman, Kieran L O'Loughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2005
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cellsYuexing Zhang, Xin-Wei Wang, Danijela Jelovac, et al.
Cancer Research|July 23, 2003
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transportZhe-Sheng Chen, Robert W Robey, Martin G Belinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemiasKen Shiozawa, Takeo Nakanishi, Ming Tan, et al.
Molecular Pharmacology|November 15, 2012
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cellsAlex Man Lai Wu, Pooja Dalvi, Xiaoli Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trialJudith E Karp, Douglas D Ross, Weidong Yang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 10, 2011
Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residentsDouglas D Ross, Deborah W Shpritz, Susan D Wolfsthal, et al.
The Journal of Biological Chemistry|December 7, 2007
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cellsYingqiu Xie, Kexin Xu, Douglas E Linn, et al.
Molecular Pharmacology|July 19, 2003
Molecular modes of action of artesunate in tumor cell linesThomas Efferth, Axel Sauerbrey, Armin Olbrich, et al.
Pageof 6